2 Stocks to Buy on the Dip and Hold for 10 Years
DexCom has significant room to grow in its core market, despite disappointing results last year.
10 stocks we like better than Novo Nordisk ›
One of Warren Buffett's famous pieces of investing advice is to be greedy when others are fearful. One way to apply this wisdom is to look for companies that have lagged the market recently but still appear to be excellent long-term investment opportunities.
Two great examples today in the healthcare sector are Novo Nordisk (NYSE: NVO) and DexCom (NASDAQ: DXCM). Although these two corporations have encountered significant headwinds since last year, they could deliver market-beating returns to investors who initiate positions today and stick with them for at least a decade.
Novo Nordisk is coming off clinical setbacks and unimpressive financial results, at least by its lofty standards. The stock has significantly underperformed the market over the trailing-12-month period. But after this beating, the company's shares look attractive. Here are several reasons why.
First, although Novo Nordisk's eternal rival, Eli Lilly, appears to be taking the lead in the fast-growing weight management market, the former still has excellent prospects in this rapidly expanding therapeutic area.
Novo Nordisk's Wegovy continues to grow its sales at a good clip, and the company is awaiting approval from the U.S. Food and Drug Administration for an oral formulation of this popular medicine. Further, Novo Nordisk has promising internally developed pipeline candidates, such as amycretin, which recently entered phase 3 studies.
The Denmark-based drugmaker has also enhanced its pipeline in this area, thanks to licensing deals and acquisitions.
Second, Novo Nordisk has been working on diversifying its lineup and currently has promising pipeline candidates outside of its core treatment areas of diabetes and obesity. Novo Nordisk is developing medicines for conditions including hemophilia, Parkinson's disease, sickle cell disease, Alzheimer's disease, and others.
Third, after being southbound for the past 12 months, Novo Nordisk's shares look reasonably valued. The company's forward price-to-earnings ratio is 16.8, compared to the 16.3 average for the healthcare industry. Novo Nordisk's financial results over the past year have been terrific by industry standards, but not quite what the market expected. That may have justified the sell-off, but at current levels, the stock looks attractive.
Finally, Novo Nordisk is a solid dividend-paying company. It has increased its annual dividend per share by almost 284% over the past decade, while offering a forward yield of 2.3%. That's not exceptional, but it's above the S&P 500 index's average of 1.3%. Novo Nordisk is well-positioned to bounce back and deliver strong returns in the next decade as it rides weight management (and other) tailwinds.
DexCom is a leading diabetes-focused medical device company. It develops continuous glucose monitoring (CGM) systems that help diabetics with constant blood sugar level measurements. DexCom has been successful thanks to the increased adoption of this innovative technology. Unlike blood glucose meters that are manually operated, use pesky and painful fingersticks, and can only tell a person's sugar level at one point in time, CGM devices are constantly monitoring things and automatically make measurements as often as every five minutes.
Rrevenue and earnings have grown rapidly over the past decade, but the company hit a speed bump last year when its top-line growth slowed considerably, partly due to higher-than-expected rebates in the U.S., resulting in lower revenue per patient. That said, these are short-term issues that do little to impact the company's long-term prospects. And on that front, there are still plenty of reasons to be excited about DexCom's future.
Consider that the company has ample room to grow, even in the U.S., a country that enjoys higher CGM penetration than most others. However, as DexCom has consistently pointed out, the population of patients who use CGM continues to lag behind those who are eligible for third-party coverage -- in other words, many people could obtain the technology paid for by insurers but have not yet opted in.
Further, there is a vast worldwide opportunity, since only a tiny percentage of the diabetics in the world use CGM technology. Though many are in countries where DexCom does not do business, the company has generally increased its addressable market by entering new geographies. In the next 10 years, expect the company to do the same while benefiting from greater insurance coverage for CGM -- third-party payers, including governments, have been more willing to foot the bill because of the technology's benefits.
All that should lead to consistent revenue and earnings growth for the medical device specialist. The stock has crushed the market in the past decade using this formula. In my view, it is well-positioned to do the same through 2035.
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!*
Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 30, 2025
Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends DexCom and Novo Nordisk and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy.
2 Stocks to Buy on the Dip and Hold for 10 Years was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
19 minutes ago
- New York Times
Rockets want to balance experience with youth
A deal involving seven teams highlights the weekend. Meanwhile, several agreed-upon transactions are becoming official. Jacob Kupferman / Getty Images Over the past few weeks, Houston Rockets team officials made it clear that building on a 52-win season was the organization's No. 1 priority, regardless of its postseason embarrassment months before. Houston's brass, led by general manager Rafael Stone and owner Patrick Fertitta, aggressively retained its core. Head coach Ime Udoka was signed to a long-term extension, strengthening the alignment that has worked the past two years. Key veteran contributors Fred VanVleet and Steven Adams were next on the docket, their immediate futures hammered out quickly. Important role players — Aaron Holiday, Jeff Green and Jae'Sean Tate — were also re-signed, as was fourth-year forward Jabari Smith Jr., an Udoka favorite. The trade for 14-time All-Star forward Kevin Durant (which can't be officially completed until July 6), a blockbuster move that cost the Rockets two starters and NBA Draft capital, was the biggest indicator that Houston intended to contend. During the first few hours of free agency, the organization doubled down on those intentions. Then, Monday, the Rockets agreed to sign veteran forward Dorian Finney-Smith to a four-year, $53 million deal, according to league sources. Houston also agreed to a deal to reacquire former center Clint Capela, one that will pay the 31-year-old $21.5 million over the next three seasons, a league source said. Houston isn't finished doing business, either. GO FURTHER Rockets want to balance experience with youth, and they're off to a great start The Thunder announced that doctors will re-evaluate All-NBA forward Jalen Williams in 12 weeks. Williams underwent surgery on his right wrist. Twelve weeks from today is Sep. 23, approximately one week before the start of training camp. Getty Images As vital systems go, the spine can be grossly underappreciated. Respected but not celebrated. The supporting role it plays, the way it silently factors in all functionalities, is often overlooked. Until it hurts. Until something doesn't work. However, the spine, those who have been exposed to its intrinsic value know, is vital to overall health. It manages balance, enables flexibility. It absorbs shock. It protects the spinal cord, the communication highway between the brain and the rest of the body. The Golden State Warriors have lost their backbone. That was Kevon Looney. That's what he meant by who they were and how they sustained success for so long. GO FURTHER As Kevon Looney leaves the Warriors, so does the dynasty's backbone The Raptors have agreed to an extension for Jakob Poeltl, per a team source. He will opt into his $19.5 million player option for 2026-27 and sign for three more years. The final year, in 2029-30, is partially guaranteed. The four extra years beyond this one will be worth a maximum of $104 million. Poeltl is the Raptors' starting center, and they have been far better with him on the floor than off it since they acquired him from the San Antonio Spurs in 2023. Getty Images The LA Clippers headed into free agency having handled the expected items. James Harden was who president of basketball operations Lawrence Frank declared as the team's 'top priority' following the draft. He is back, with a player option for 2026. Frank said it was 'a dark day' when backup power forward Nicolas Batum was included in the trade that brought Harden to LA from the Philadelphia 76ers in the fall of 2023, signaling an intention for Batum to be back. Like Harden, Batum declined his player option and signed a new deal with the Clippers that gave him a raise, while the Clippers have a team option on Batum in 2026. I identified two needs for the Clippers, ones that mirrored their needs for the draft but were more acute because the Clippers needed short-term playable options: ball handling and frontcourt help. One of my named targets was Milwaukee Bucks center Brook Lopez. My inclusion of Lopez, who turned 37 years old in April, had as much to do with the connections as it did with basketball. Read more below. GO FURTHER Clippers begin free agency by adding Brook Lopez. Could Chris Paul be next? Getty Images Day 1 of free agency is in the books, and we don't really have the big free agent everybody is looking to grab this year. We mostly have a lot of trades happening, and teams wondering if Giannis Antetokounmpo is going to give up on being with the Milwaukee Bucks for life. Teams around the league are still trying to figure out life in the era of the crippling second apron, and we're seeing teams fully start to grasp how much they need to avoid that Trojan horse hard cap the owners worked into the collective bargaining agreement. Still, we had a lot happen through the first official day of free agency. All of that and more is covered below. GO FURTHER NBA free agency 2025: Grades, head-scratchers and more analysis from Day 1 Sando Mamukelashvili's contract with Toronto would leave the Raptors slightly in the luxury tax, with the potential to end up deeper if incentives on Jakob Poeltl, Immanuel Quickley and R.J. Barrett hit. A simple way to take the tax out of play would be trade Ochai Agbaji — owed $6.4 million in the final year of his contract — and then sign second-round pick Alijah Martin into the Raptors' 14th roster spot. Kevin Sousa / Getty Images The Toronto Raptors have agreed to sign 26-year-old big man Sandro Mamukelashvili to a two-year, $5.5 million contract with a second year player option, a team source confirmed. Mamukelashvili averaged 6.3 points per game for the San Antonio Spurs last season. Getty Images For so long, Trae Young seemed destined for an eventual trade. The Atlanta Hawks' All-Star guard was always a tremendous playmaker, but his ball dominance and defensive vulnerability made building a contender around him a quagmire. It meant Young lived in trade rumors every silly season. The Hawks made the Eastern Conference Finals years ago with Young, so there had to be a solution to get there once again. Now, after a dramatic yearlong makeover, the Hawks may have a shot at returning. Following years of Young trade rumors, the Hawks have built a team optimized to fit around the recently evolved version of him. GO FURTHER Hawks' rapid rebuild around Trae Young comes full circle, so is he still Atlanta's future? Getty Images There has been a lot said about the rapid influx of money into the NBA in recent years. The league is now minting future billionaires. It will likely soon have its first player making $100 million annually. The owners are doing fine, too, in case anyone had their concerns — the Los Angeles Lakers just sold at a $10 billion valuation, if you hadn't heard. But Sunday's contract agreement between the Houston Rockets and Jabari Smith Jr. felt like an inflection point. It felt like the NBA's first deal where there was just too much money to pass up. Smith intends to sign a five-year, $122 million extension with the Rockets. It was a bit surprising because Smith has not been supremely impressive since he went No. 3 in the 2022 NBA Draft, and Houston has a deep well of promising young talent it will need to pay soon, while also facing encroaching cap issues. The Rockets had until October to negotiate an extension with Smith but it did not seem like a pressing concern. They got a deal done, though. GO FURTHER What Jabari Smith Jr.'s extension tells us about the state of NBA player salaries Alex Slitz / Getty Images League sources say Damian Lillard is elated with the Bucks' decision to waive and stretch his contract, as it puts him in the kind of basketball-first position that few All-Star level players, if any, have experienced in league history. In short, he'll be able to join the contending team of his choosing, either sometime soon or perhaps next summer, without the financial aspect of the decision playing a significant part. With Lillard owed $54.1 million for this coming season and $58.4 million in the 2026-27 campaign, there is a salary offset for any team that acquires him during that two-year period. And while the Bucks would surely prefer that Lillard sign for a significant salary as a way to alleviate some of their financial burden, the reality is that he could sign for a minimum-salary deal and still be paid the same amount. That's a powerful place to be when you're a future Hall of Famer in your mid-30s who has never won a championship. Not surprisingly, league sources say Lillard received calls from several contending teams very quickly after the news of his Bucks' ending broke. The question now is whether he wants to sign with a team now and rehabilitate while under their care or wait until next summer to reassess the situation. All in all, it's a dream scenario for Lillard. Especially considering he might have been heading for a change of scenery even before his injury. GO FURTHER Bucks waiving Damian Lillard to make room to sign Myles Turner: Sources Getty Images The Lakers' timeline situation ever since Luka Dončić was gifted to them back in early February has looked bizarre. Life was almost simpler before that trade. They could've aimed to ride out the LeBron James-Anthony Davis chapter until the wheels fell off. From there, they could've started selling Lakers mystique to new big stars in hopes of furthering their legacy and hanging more banners. Maybe it's not a foolproof plan and super easy to execute, but it's worked enough times in the franchise's history. And it worked after they signed LeBron back in 2018. Then, Dallas sent Dončić to the Lakers, which has changed just about everything. The Lakers now have to start playing for the future and present-day championship stability. The funny thing is lead executive Rob Pelinka was already trying to toe that line, as he wasn't ready to relinquish assets for another LeBron-Davis-led championship pursuit. Now, the Lakers must build around Dončić and aim for championship stability. The problem is LeBron is still very much on this team. Before free agency opened, he picked up his $52.6 million player option for the 2025-26 season. It will be his 23rd season, just a mind-boggling number when you consider his résumé, mileage and current production. GO FURTHER LeBron James is no longer the Lakers' top priority. What's next for both parties? Both Detroit and Sacramento would benefit from turning Dennis Schröder's signing in Sacramento into a sign-and-trade. Detroit would gain a large trade exception — likely $14.1 million — they could potentially use in another deal this summer to bring in talent, while the Kings could take Schröder into their existing $16.8 million Kevin Hurter trade exception and leave their nontaxpayer midlevel exception open for other free agency moves. Because Schröder's deal is for three years, a sign-and-trade would be allowable. John Fisher / Getty Images Jericho Sims has agreed to a two-year contract to return to the Milwaukee Bucks, with the second year a player option, a league source confirmed to The Athletic. Gregory Shamus / Getty Images Dennis Schröder has agreed to a 3-year, $45 million contract with the Sacramento Kings, a league source confirmed. The Kings will be Schröder's 10th NBA team and fourth in the last nine months. The common theme in the Rockets' in-house business or their outward acquisitions is experience. Fred VanVleet, Steven Adams and Clint Capela are 31. Dorian Finney-Smith is 32. Kevin Durant is 36. As long as Ime Udoka has been at the helm, his voice within the organization has risen, and the 47-year-old has been vocal about his preference for older veterans. And as such, given the aforementioned alignment with Houston's front office and ownership, the team has fulfilled his wishes. After Houston's Game 7 loss to the Golden State Warriors, Udoka's end-of-season news conference drove home the point about the need for improved IQ and the power of experience, buzzwords that typically precede roster changes. Make no mistake: The Rockets' offseason is off to an excellent start. The overarching theme in negotiations has been maintaining financial leverage, all while building a roster that is built for now and later. The two-timeline approach is risky in a vacuum, but context, mainly personnel, is important. It might not have worked out in the Bay with James Wiseman and Jonathan Kuminga, but those are different players from Amen Thompson, Jabari Smith, Tari Eason and even Reed Sheppard. Still, it's jarring to see Houston move in this manner, particularly because of how quickly its methodology has shifted. Perhaps that's why it's difficult to quantify the magnitude of its summer business to this point. For years, the Rockets' ethos was patience and perseverance, opting to accumulate losses, build through the draft and maintain enough elasticity to capitalize at an opportune moment. That moment is now. The Rockets have peeled back the curtain on what was once a rebuild, laying out a championship-capable core. Read more on Houston's active start to free agency here. GO FURTHER Rockets want to balance experience with youth, and they're off to a great start Geoff Burke / Imagn Not only is the Jonas Valančiūnas acquisition great on the floor for the Nuggets, it gives Nikola Jokić an old foil for a teammate. Jokić joked about their joint physicality last December, when he scored a career-high 56 points, along with 16 rebounds and 8 assists against the Wizards – and Valančiūnas, who was then in Washington and who spent most of the night in a pitched, hard-nosed but good-natured battle with the Joker. Valančiūnas did just fine as well, with 20 points, 12 rebounds, 5 blocks and 5 assists in an improbable Wizards win. 'I had a couple of really good wrestling moves down there with Jonas,' Jokić said afterward. 'I think Jonas's wrestling, it's always interesting. I always talk to him normally, and it's always a little bit physical. I mean, it should be. We're big boys from Europe. We're kind of used to being in the contact. I think that's how it's supposed to be. Good rivalry.' GO FURTHER Nuggets waste Nikola Jokić's career night in inexplicable loss to woeful Wizards New Knicks signee Guerschon Yabusele is a good player and a good fit that fills a need. He can play the 5 and run next to Karl-Anthony Towns or Mitchell Robinson. Opponents need to guard him beyond the arc. I'm not obsessed with the second-year player option, given the Knicks' potential 2026-27 payroll. But sometimes that's the cost of doing business for a good player. Isaiah J. Downing / Imagn While everyone else is focused on the Bucks right now, the Dario Sarić for Jonas Valančiūnas trade is an absolutely incredible deal for the Denver Nuggets. They just traded $5 million in dead weight to the Sacramento Kings to get the best backup center of the Nikola Jokić era. Denver now is $2.4 million below the luxury tax line with at least on roster spot to fill. If that spot is a veteran minimum deal for $2.3 million, they will just barely stay under the tax and avoid the repeater penalty this year. Page 2
Associated Press
27 minutes ago
- Associated Press
Obesity drug prices are dropping, but getting a steady supply remains a challenge
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without insurance — out of reach for many patients. And even for people with insurance, coverage remains uneven. 'The medications should be available, the question is at what price and can people sustain that,' said Matt Maciejewski, a Duke University professor who studies obesity treatment coverage. Doctors say the situation forces them to get creative in treating patients, but there's hope that prices may fall more in the future. The drugs are still in high demand Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity. Zepbound brought in $2.3 billion in U.S. sales during this year's first quarter, making it one of drugmaker Eli Lilly's best sellers. Novo Nordisk says Wegovy has about 200,000 weekly prescriptions in the U.S., where it brought in nearly $1.9 billion in first-quarter sales. Insurance coverage is increasing — for some The benefits consultant Mercer says more businesses with 500 or more employees are adding coverage of the injected drugs for their workers and family members. And Novo says 85% of its patients who have coverage in the U.S. pay $25 or less per month. Plus some patients with diabetes can get coverage of the GLP-1 drugs Ozempic and Mounjaro from Novo and Lilly that are approved to treat that condition. But most state and federally funded Medicaid programs don't cover the drugs for obesity and neither does Medicare, the federal program mainly for people age 65 and older. Even the plans that cover the drugs often pay only a portion of the bill, exposing patients to hundreds of dollars in monthly costs, said Dr. Beverly Tchang. Drugmakers offer help with these out-of-pocket costs, but that assistance can be limited. 'Coverage is not the same as access,' said Tchang, a New York-based doctor who serves as a paid advisor to both Novo and Lilly. But coverage remains inconsistent Bill-payers like employers are nervous about drugs that might be used by a lot of people indefinitely. Some big employers have dropped coverage of the drugs due to the expense. Pharmacy benefit managers, or PBMs, also are starting to pick one brand over the other as they negotiate deals with the drugmakers. One of the nation's largest PBMs, run by CVS Health, dropped Zepbound from its national formulary, or list of covered drugs, on July 1 in favor of Wegovy. That forced Tchang to figure out another treatment plan for several patients, many of whom took Zepbound because it made them less nauseous. Dr. Courtney Younglove's office sends prospective patients a video link showing them how to check their insurer's website for coverage of the drugs before they visit. 'Then some of them just cancel their appointment because they don't have coverage,' the Overland Park, Kansas, doctor said. Cheaper compounded drugs are still being sold Compounding pharmacies and other entities were allowed to make off-brand, cheaper copies of Wegovy and Zepbound when there was a shortage of the drugs. But the U.S. Food and Drug Administration determined earlier this year that the shortage had ended. That should have ended the compounded versions, but there is an exception: Some compounding is permitted when a drug is personalized for the patient. The health care company Hims & Hers Health offers compounded doses of semaglutide, the drug behind Wegovy, that adjust dose levels to help patients manage side effects. Hims says these plans start at $165 a month for 12 months, with customers paying in full upfront. It's a contentious issue. Eli Lilly has sued pharmacies and telehealth companies trying to stop them from selling compounded versions of its products. Novo recently ended a short-lived partnership with Hims to sell Wegovy because the telehealth company continued compounding. Novo says the compounded versions of its drug put patient safety at risk because ingredients are made by foreign suppliers not monitored by US regulators. Hims says it checks all ingredients to make sure they meet U.S. quality and safety standards. It also uses a third-party lab to verify that a drug's strength is accurately labeled. Prices have dropped Both drugmakers are selling most of their doses for around $500 a month to people without insurance, a few hundred dollars less than some initial prices. Even so, that expense would eat up about 14% of the average annual per person income in the U.S., which is around $43,000. There are some factors that may suppress prices over time. Both companies are developing pill versions of their treatments. Those could hit the market in the next year or so, which might drive down prices for the older, injectable doses. Younglove said some of her patients save as much as 15% by getting their doses shipped from a pharmacy in Canada. They used to get them from an Israeli pharmacy until the Canadians dropped their prices. She says competition like this, plus the introduction of pill versions, will pressure U.S. prices. 'I think price wars are going to drive it down,' she said. 'I think we are in the early stages. I have hope.' ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group. The AP is solely responsible for all content.
Skift
27 minutes ago
- Skift
First-Half Review: 2025's Top 10 Developments, So Far
Skift Take If a week is a long time in politics, then six months in the airline industry can feel like a lifetime. It's been a tumultuous start to 2025, even by the standards of this least predictable of sectors, and don't expect things to slow down much as we enter Q3. In this week's feature story, we briefly hit pause to reflect on the first-half of the year. Don't miss the Airline Weekly team's top 10 developments of 2025, so far.
